China's ImmuneOnco drops most in 6 months on discounted share sale
** Shares of ImmuneOnco Biopharmaceuticals Shanghai 1541.HK drop 13.5% to HK$14.41, on course for their biggest one-day pct decline since April 7 ** The China-based tumor immunotherapy developer plans sale of 24.2 mln new shares to third party investors in share placement, raising HK$350.9 mln ($45.10 mln) for R&D of therapy for treatment of solid tumors in China, among others ** The new shares will be issued at HK$14.50 apiece, or nearly 13% discount to Wednesday close of HK$16.66 each ** YTD, stock up 180.8%, Hang Seng Biotech Index .HSBIO up 104.6% ($1 = 7.7806 Hong Kong dollars) (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S